Semaglutide versus Liraglutide for higher Weight Loss in overweight Patients

被引：0
|
作者：
Rubino, D. M.
机构：
来源：
AKTUELLE ERNAHRUNGSMEDIZIN | 2022年 / 47卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：165 / 165
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
    Xie, Zeyu
    Yang, Sensen
    Deng, Weishang
    Li, Jinjian
    Chen, Jisheng
    CLINICAL EPIDEMIOLOGY, 2022, 14 : 1463 - 1476
  • [2] Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
    Ghusn, Wissam
    De la Rosa, Alan
    Sacoto, Daniel
    Cifuentes, Lizeth
    Campos, Alejandro
    Feris, Fauzi
    Hurtado, Maria Daniela
    Acosta, Andres
    JAMA NETWORK OPEN, 2022, 5 (09) : E2231982
  • [3] One-Year Weight Loss in Patients With Obesity on Semaglutide or Liraglutide in Clinical Practice
    Gasoyan, Hamlet
    Pfoh, Elizabeth
    Schulte, Rebecca
    Le, Phuc
    Butsch, W. Scott
    Rothberg, Michael
    OBESITY, 2024, 32 : 43 - 43
  • [4] In overweight or obesity without diabetes, weekly semaglutide vs. daily liraglutide increased weight loss at 68 wk
    Kauffman, Robert P.
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (05) : JC56 - JC56
  • [5] Real-world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting
    Trinh, Huong
    Donovan, Anthony
    McAdam-Marx, Carrie
    DIABETES OBESITY & METABOLISM, 2025,
  • [6] Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
    Rodriguez, Patricia J.
    Goodwin Cartwright, Brianna M.
    Gratzl, Samuel
    Brar, Rajdeep
    Baker, Charlotte
    Gluckman, Ty J.
    Stucky, Nicholas L.
    JAMA INTERNAL MEDICINE, 2024, 184 (09) : 1056 - 1064
  • [7] Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity
    Mares, Adriana C.
    Chatterjee, Saurav
    Mukherjee, Debabrata
    CURRENT OPINION IN CARDIOLOGY, 2022, 37 (04) : 350 - 355
  • [8] ESG PLUS LIRAGLUTIDE IS SUPERIOR TO ESG ALONE FOR WEIGHT LOSS IN OVERWEIGHT AND OBESE PATIENTS
    Badurdeen, Dilhana
    Hoff, Anna Carolina
    Hedjoudje, Abdellah
    Itani, Mohamad I.
    Farha, Jad
    Kalloo, Anthony N.
    Khashab, Mouen A.
    Neto, Manoel Galvao
    Barrichello, Sergio A.
    Kumbhari, Vivek
    GASTROINTESTINAL ENDOSCOPY, 2020, 91 (06) : AB215 - AB215
  • [9] Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes
    Del Prete, Michela
    Gavazzi, Lidia
    Disoteo, Olga Eugenia
    Vignati, Federico
    Di Sacco, Gianleone
    Muratori, Fabrizio
    EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY, 2025, 30 (01)
  • [10] Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis
    Azuri, Joseph
    Hammerman, Ariel
    Aboalhasan, Enis
    Sluckis, Ben
    Arbel, Ronen
    OBESITY, 2023, 31 (06) : 1510 - 1513
12345